Feverfew (Tanacetum parthenium L.): A systematic review

Pharmacognosy Reviews

Volumn 5, Issue 9, 2011, Pages 103-110

  Pareek, Anil ^a   Suthar, Manish ^b   Rathore, Garvendra S ^b   Bansal, Vijay ^a  

^a L M College of Science and Technology (Pharmacy Wing)   (India)

^b Bharat Sewak Shiksha Samiti   (India)

Author keywords

Anti inflammatory; migraine; parthenolide; Tanacetum parthenium

Indexed keywords

3 BETA HYDROXY PARTHENOLIDE; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALPHA PHELLANDRENE; ALPHA THUJENE; APIGENIN; BORNEOL; BORNYL ACETATE; CAMPHENE; CAMPHOR; CARBON DIOXIDE; CARVACROL; CARYOPHYLLENE OXIDE; COSTUNOLIDE; EPOXYSANTAMARIN; EUDESMANOLIDE DERIVATIVE; EUGENOL; GERMACRANOLIDE DERIVATIVE; GUAIANOLIDE DERIVATIVE; ISOBORNYL THIOCYANOACETATE; LUTEOLIN; PARTHENOLIDE; PLACEBO; QUERCETIN; SECOTANAPARTHENOLIDE; SESQUITERPENE LACTONE; TANACETUM PARTHENIUM EXTRACT; UNCLASSIFIED DRUG; WARFARIN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CHEMICAL COMPOSITION; COMMON COLD; CONSTIPATION; COUGHING; DERMATITIS; DNA REPLICATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; FATIGUE; FEVER; GENOTOXICITY; HEADACHE; HEART RATE; HISTAMINE RELEASE; HUMAN; IC 50; INSECT BITE; INSOMNIA; JOINT STIFFNESS; MIGRAINE; MINIMUM INHIBITORY CONCENTRATION; MOUTH INFLAMMATION; MOUTH SWELLING; MOUTH ULCER; MUSCLE STIFFNESS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NERVOUSNESS; NONHUMAN; OTALGIA; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SLEEP PATTERN; SPONTANEOUS ABORTION; STOMACH PAIN; SYSTEMATIC REVIEW; TANACETUM PARTHENIUM; TINNITUS; TOOTH PAIN; TREATMENT RESPONSE; VASCULAR SMOOTH MUSCLE; VERTIGO;

ASTERACEAE; HEXAPODA; TANACETUM PARTHENIUM;

EID: 79955112624     PISSN: 09737847     EISSN: 09762787     Source Type: Journal    
DOI: 10.4103/0973-7847.79105     Document Type: Review

References (62)

1. Duke JA . CRC Handbook of Medicinal Herbs. Boca Raton, FL: CRC Press; 1985.
2. Jackson B, McDonald RL. In: Dobelis IN, editor. Magic and Medicine of Plants. Pleasantville, NY: Reader's Digest Assoc.; 1986.
3. Meyer JE. The Herbalist. Hammond, IN: Hammond Book Co.; 1934.
4. Castleman M. The Healing Herbs. Emmaus, PA: Rodale Press; 1991.
5. Chavez M, Chavez P. Feverfew. Hosp Pharm. 1999;34:436-61. (Pubitemid 30176279)
6. Jain NK, Kulkarni SK. Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats. J Ethnopharmacol 1999;68:251-9. (Pubitemid 29502482)
7. Heptinstall S, Awang DW, Dawson BA, Kindack D, Knight DW. Parthenolide Content and Bioactivity of Feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of Commercial and Authenticated Feverfew Products. J Pharm Pharmacol 1992;44:391-5.
8. Setty AR, Sigal AH. Herbal medications commonly used in the practice of rheumatology: Mechanisms of action, efficacy, and side effects. Semin Arthritis Rheum 2005;34:773-84. (Pubitemid 40732452)
9. Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004;1:2286.
10. Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol 1992;43:2313-20.
11. Bohlmann F, Zdero C. Sesquiterpene Lactones and Other Constituents from Tanacetum parthenium. Phytochemistry 1982;21:2543-9.
12. Groenewegen WA, Knight DW, Heptinstall S. Compounds extracted from feverfew that have anti-secretory activity contain an alpha-methylene butyrolactone unit. J Pharm Pharmacol 1986;38:709-12. (Pubitemid 16038927)
13. Milbrodt M, Schroder F, Konig W. 3,4-Epoxy-8-deoxycumambrin B, A sesquiterpene lactone from Tanacetum parthenium. Phytochemistry 1997;44:471-4. (Pubitemid 27100309)
14. Begley M, Hewlett M, Knight D. Revised structures for guaianolidemethylenebutyro- lactones from feverfew. Phytochemistry 1989;28:940-3.
15. Williams CA, Harborne JB, Eagles J. Variations in lipophilic and polar flavonoids in the genus Tanacetum. Phytochemistry 1999;52:1301-6. (Pubitemid 30021681)
16. Williams CA, Harborne JB, Geiger H, Hoult JR. The flavonoids of Tanacetum parthenium and T. vulgare and their antiinflammatory properties. Phytochemistry 1999;51:417-23. (Pubitemid 29266276)
17. Williams CA, Hoult JR, Harborne JB, Greenham J, Eagles J. A biologically active lipophilic flavonol from Tanacetum parthenium. Phytochemistry 1995;38:267-70.
18. Long C, Sauleau P, David B. Bioactive flavonoids of Tanacetum parthenium revisited. Phytochemistry 2003;64:567-9. (Pubitemid 37168977)
19. Hall I, Lee K, Starnes C, Sumida Y, Wu R, Waddell T. Antiinflammatory activity sesquiterpene lactones and related compounds. J Pharm Sci 1979;68:537-42. (Pubitemid 9186368)
20. Akpulat H, Tepe B, Sokmen A, Daferera D, Polissiou M. Composition of the essential oils of Tanacetum argyrophyllum (C. Koch) Tvzel. var. argyrophyllum and Tanacetum parthenium (L.) Schultz Bip. (Asteraceae) from Turkey. Biochem Syst Ecol 2005;33:511-6. (Pubitemid 40359249)
21. Kisiel W, Stojakowska A. A sesquiterpene coumarin ether from transformed roots of Tanacetum parthenium. Phytochemistry 1997;46:515-6. (Pubitemid 27414933)
22. Laiking S, Brown G. Coniferaldehyde derivatives from tissue culture of Artemisia annua and Tanacetum parthenium. Phytochemistry 1999;50:781-5. (Pubitemid 29135040)
23. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The antiinflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 2001;8:759-66. (Pubitemid 32752455)
24. Collier HO, Butt NM, McDonald WJ, Saeed SA. Extract of feverfew inhibits prostaglandin biosynthesis. Lancet 1980;2: 922-3. (Pubitemid 10014336)
25. Brown AM, Edwards CM, Davey MR, Power JB, Lowe KC. Pharmacological activity of feverfew (Tanacetum parthenium [L.] Schultz-Bip.): Assessment by inhibition of human polymorphonuclear leukocyte chemiluminescence in vitro. J Pharm Pharmacol 1997;49:558-61. (Pubitemid 27229482)
26. Loecshe EW, Mazurov AV, Voyno-Yasenetskaya TA, Groenewegnen WA, Heptinstall S, Repin VS. Feverfew-an antithrombotic drug?. Folia Haematol Int Mag Klin Morphol Blutforsch 1988;115:181-4.
27. Makheja AN, Bailey JM. The active principle in feverfew. Lancet 1981;2:1054-7.
28. Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1985;1:1071-4. (Pubitemid 15075508)
29. Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukot Med 1982;8:653-60. (Pubitemid 12123354)
30. Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol 1988;40:743-5.
31. Neill LA, Barrett ML, Lewis GP. Extracts of feverfew inhibit mitogen-induced human peripheral blood mononuclear cell proliferation and cytokine mediated responses: A cytotoxic effect. Br J Clin Pharmacol 1987;23:81-3. (Pubitemid 17101827)
32. Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew extracts and parthenolide irreversibly inhibit vascular responses of the rabbit aorta. J Pharm Pharmacol 1992;44:737-40.
33. Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew and vascular smooth muscle: Extracts from fresh and dried plants show opposing pharmacological profiles, dependent upon sesquiterpene lactone content. Planta Med 1993;59:20-5. (Pubitemid 23055640)
34. Barsby RW, Knight DW, McFadzean I. A chloroform extract of the herb feverfew blocks voltage-dependent potassium currents recorded from single smooth muscle cells. J Pharm Pharmacol 1993;45:641-5. (Pubitemid 23226757)
35. Bejar E. Parthenolide inhibits the contractile responses of rat stomach fundus to fenfluramine and dextroamphetamine but not serotonin. J Ethnopharmacol 1996;50:1-12. (Pubitemid 26028890)
36. Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behavior via neutralization of sulphydryl groups. J Pharm Pharmacol 1987;39:459-65. (Pubitemid 17114404)
37. Yasenetskaya TA, Loesche W, Groenewegen WA, Heptinstall S, Repin VS, Till U. Effects of an extract of feverfew on endothelial cell integrity and on cAMP in rabbit perfused aorta. J Pharm Pharmacol 1988;40:501-2.
38. Heptinstall S, Groenewegen S, Spangenberg P, Losche W. Inhibition of platelet behaviour by feverfew: A mechanism of action involving sulphydryl groups. Folia Haematol Int Mag Klin Morphol Blutforsch 1988;115:447-9.
39. Krause S, Arese P, Heptinstall S, Losche W. Influence of substances affecting cell sulfhydryl/disulfide status on adherence of human monocytes. Arzneimittelforschung 1990;40:689-92. (Pubitemid 20199601)
40. Hayes NA, Foreman JC. The activity of compounds extracted from feverfew on histamine release from rat mast cells. J Pharm Pharmacol 1987;39:466-70. (Pubitemid 17114405)
41. Tiuman TS, Ueda-Nakamura T, Garcia Cortez DA, Dias Filho BP, Morgado-Díaz JA, de Souza W, et al. Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother 2005;49:176-82. (Pubitemid 40065790)
42. Zhang S, Ong CN, Shen SM. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 2004;208:143-53. (Pubitemid 38624155)
43. Zhang S, Ong CN, Shen HM. Involvement of proapoptotic Bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis. Cancer Lett 2004;211:175-88. (Pubitemid 38824631)
44. Ross JJ, Arnason JT, Birnboim HC. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med 1999;65:126-9. (Pubitemid 29138143)
45. Miglietta A, Bozzo F, Gabriel L, Bocca C. Microtubule-interfering activity of parthenolide. Chem Biol Interact 2004;149:165-73. (Pubitemid 39387218)
46. Kapadia GJ, Azuine MA, Tokuda H, Hang E, Mukainaka T, Nishino H, et al. Inhibitory effect of herbal remedies on 12-O-tetradecanoylphorbol-13-acetate- promoted Epstein-Barr virus early antigen activation. Pharmacol Res 2002;45:213-20. (Pubitemid 35418364)
47. Feverfew-a new drug or an old wives' remedy? Lancet 1985;1:1084.
48. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J 1985;291:569-73. (Pubitemid 15225459)
49. Waller PC, Ramsay LE. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J 1985;291:1128. (Pubitemid 16240994)
50. Murphy JJ, Heptinstall S, Mitchell JL. Randomised doubleblind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;2:189-92.
51. Groenewegen WA, Knight DW, Heptinstall S. Progress in the medicinal chemistry of the herb feverfew. Prog Med Chem 1992;29:217-38.
52. Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. Lancet 1982;2:776.
53. Pfaffenrath V, Diener HC, Fischer M, Friede M, Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis-a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002;22:523-32. (Pubitemid 36609346)
54. Awang DV. Fever few: A headache for the consumer. HerbalGram 1993;29:34-5.
55. Losche W, Mazurov AV, Heptinstall S, Groenewegen WA, Repin VS, Till U. An extract of feverfew inhibits interactions of human platelets with collagen substrates. Thromb Res 1987;48:511-8.
56. DeWeerdt C, Bootsma H, Hendriks H. Herbal medicines in migraine prevention. Randomized double-blind placebocontrolled crossover trial of a feverfew preparation. Phytomedicine 1996;3:225-30. (Pubitemid 126504561)
57. Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: A double blind, placebo controlled study. Ann Rheum Dis 1989;48:547-9. (Pubitemid 19186590)
58. Smith TH, Liu X. Feverfew extracts and the sesquiterpene lactone parthenolide inhibit intercellular adhesion molecule-1 expression in human synovial fibroblasts. Cell Immunol 2001;209:89-96. (Pubitemid 32662306)
59. Palevitch D. Feverfew (Tanacetum parthenium) as prophylactic treatment for migraine: A double-blind placebo-controlled study. Phytother Res 1997;11:508-11. (Pubitemid 27460633)
60. Miller LG. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158:2200-11. (Pubitemid 28512494)
61. Vickers HR. Feverfew and migraine. Br Med J 1985;291:827.
62. Anderson D, Jenkinson PC, Dewdney RS, Blowers SD, Johnson ES, Kadam NP. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: A comparison of chronic feverfew users and matched non-users. Hum Toxicol 1988;7:145-52. (Pubitemid 18093629)